期刊文献+

碱基切除修复与抗肿瘤药物耐药 被引量:7

Base excision repair and antineoplastic drug resistance
原文传递
导出
摘要 化疗是目前临床上治疗肿瘤的主要方法之一,抗肿瘤药物耐药则是导致肿瘤治疗失败的重要原因之一。多种化疗药物抗肿瘤的主要机制是引起DNA损伤,进而导致肿瘤细胞凋亡;因此,DNA修复功能状态与抗肿瘤药物疗效有着直接的关系。目前,已知有4种主要的DNA修复途径:碱基切除修复(base excision repair,BER)、核苷酸切除修复(nucleotide excision repair,NER)、错配修复(mismatch repair,MMR)和双键断裂修复(double strand break repair,DSBR)。其中,BER是主要的DNA修复机制之一,其修复功能异常与抗肿瘤药物耐药有着密切的联系。近年来,以BER为靶点开发了多种逆转耐药的药物或方法。本文将简要综述相关的研究进展,深入探讨抗肿瘤药物耐药的发生机制及防治措施。 Chemotherapy is one of the main methods to treat malignant tumors in clinical practice. Resistance to antineoplastic agents is one of the important reasons for treatment failure. The antineoplastic mechanism of various chemotherapeutic agents is to cause DNA damage, then result in apoptosis of tumor cells. It is suggested that the function of DNA repair is directly associated with the efficacy of antineoplastic agents. Current studies suggest that there are four major DNA repair pathways including BER (base excision repair), NER (nucleotide excision repair), MMR (mismatch repair)and DSBR (double strand break repair). Of these four pathways, BER is one of the main mechanisms of DNA repair and its malfunction is closely related to the resistance to antineoplastic agents. Recently,many kinds of agents and strategies targeting BER have been developed to reverse chemoresistance. This review summarizes the progress in research in this area and discusses the mechanism of resistance to antineoplastic agents and the potential preventive and therapeutic strategies.
出处 《肿瘤》 CAS CSCD 北大核心 2013年第3期294-298,共5页 Tumor
基金 国家重点基础研究发展计划(973计划)(编号:2010CB529402)
关键词 肿瘤 DNA修复 抗肿瘤药物 抗药性 碱基切除修复 Neoplasms DNA repair Antineoplastic agents Drug resistance Base excision repair
  • 相关文献

参考文献4

二级参考文献93

  • 1王中华,缪小平,谭文,张湘茹,徐兵河,林东昕.XRCC1单核苷酸多态与晚期非小细胞肺癌对铂类药物化疗敏感性的相关性[J].癌症,2004,23(8):865-868. 被引量:56
  • 2袁芃,缪小平,张雪梅,王中华,谭文,孙燕,张湘茹,徐兵河,林东昕.DNA损伤修复基因XRCC1和XPD遗传多态与晚期非小细胞肺癌对铂类药物的敏感性[J].中华肿瘤杂志,2006,28(3):196-199. 被引量:39
  • 3[1]Lu AL,Li X,Gu Y,et al.Repair of oxidative DNA damage:Mechanisms and functions.Cell Biochem Biophys,2001,35:141
  • 4[2]Chung HH,Kim MK,Kim JW,et al.XRCC1 R399Q polymorphism is associated with response to platinum-based neochemotherapy in bulky cervical cancer.Gynecol Oncol,2006,103 (3):1031
  • 5[3]Suh KW,Kim JH,Kim do Y,et al.Which Gene is a dominant Predictor of Response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer,the MTHFR or XRCC1 Gene? Ann Surg Oncol,2006,13 (11):1379
  • 6[4]Stoehlmacher J,Ghaderi V,Iobal S,et al.A polymorphism of the XRCC1 gene predicts for resporse to platinum based treatment in advanced colorectal cancer.Anticancer Res,2001,21 (4B):3075
  • 7[7]Quintela-Fandino M,Hitt R,Medina PP,et al.DNA -repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.J Clin Oncol,2006,24 (26):4333
  • 8[8]Sakano S,Wada T,Matsumoto H,et al.Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy.Br J Cancer,2006,95 (5):561
  • 9[9]Takala J,Ruokonen E,Webster NR,et al.Increased mortality associated with growth hormone treatment in critically ill adults.N Engl J Med,1999,341:785
  • 10[10]Simon GR,Sharma S,Cantor A,et al.ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer.Chest,2005,127 (3):978

共引文献34

同被引文献93

引证文献7

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部